Relay Therapeutics/$RLAY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Relay Therapeutics
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
Ticker
$RLAY
Sector
Primary listing
Employees
197
Headquarters
Website
RLAY Metrics
BasicAdvanced
$636M
-
-$1.92
1.63
-
Price and volume
Market cap
$636M
Beta
1.63
52-week high
$8.08
52-week low
$1.78
Average daily volume
2.2M
Financial strength
Current ratio
20.919
Quick ratio
20.193
Long term debt to equity
4.606
Total debt to equity
5.135
Profitability
EBITDA (TTM)
-335.854
Gross margin (TTM)
-3,207.32%
Net profit margin (TTM)
-3,728.89%
Operating margin (TTM)
-4,078.58%
Revenue per employee (TTM)
$40,000
Management effectiveness
Return on assets (TTM)
-28.37%
Return on equity (TTM)
-46.24%
Valuation
Price to revenue (TTM)
71.584
Price to book
0.95
Price to tangible book (TTM)
0.95
Price to free cash flow (TTM)
-2.282
Free cash flow yield (TTM)
-43.82%
Free cash flow per share (TTM)
-1.617
Growth
Revenue change (TTM)
-76.27%
Earnings per share change (TTM)
-23.94%
3-year revenue growth (CAGR)
60.60%
3-year earnings per share growth (CAGR)
-9.27%
What the Analysts think about RLAY
Analyst ratings (Buy, Hold, Sell) for Relay Therapeutics stock.
RLAY Financial Performance
Revenues and expenses
RLAY Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Relay Therapeutics stock?
Relay Therapeutics (RLAY) has a market cap of $636M as of August 30, 2025.
What is the P/E ratio for Relay Therapeutics stock?
The price to earnings (P/E) ratio for Relay Therapeutics (RLAY) stock is 0 as of August 30, 2025.
Does Relay Therapeutics stock pay dividends?
No, Relay Therapeutics (RLAY) stock does not pay dividends to its shareholders as of August 30, 2025.
When is the next Relay Therapeutics dividend payment date?
Relay Therapeutics (RLAY) stock does not pay dividends to its shareholders.
What is the beta indicator for Relay Therapeutics?
Relay Therapeutics (RLAY) has a beta rating of 1.63. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.